Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma

Zhang,Huan‑Huan; Yuan,Tai‑Ze; Li,Jian; Liang,Yin; Huang,Lai‑Ji; Ye,Jia‑Cai; Zheng,Rong‑Hui; Xie,Guo‑Feng; Zhang,Xiu‑Ping

doi:10.3892/etm.2013.1245

Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma

Authors:
- Huan‑Huan Zhang
- Tai‑Ze Yuan
- Jian Li
- Yin Liang
- Lai‑Ji Huang
- Jia‑Cai Ye
- Rong‑Hui Zheng
- Guo‑Feng Xie
- Xiu‑Ping Zhang
View Affiliations

Affiliations: Department of Radiotherapy, Tumor Hospital of Guangzhou Medical College, Guangzhou, Guangdong 510095, P.R. China
Published online on: August 2, 2013 https://doi.org/10.3892/etm.2013.1245
Pages: 1062-1066

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the effects of erlotinib combined with radiation on human nasopharyngeal carcinoma (NPC) radiosensitivity using the CNE1 and CNE2 cell lines. Human NPC cells were treated with erlotinib and/or radiation. The effect of erlotinib on the radiosensitivity of the cells was detected using a clonogenic cell survival assay. The rate of apoptosis and the cell cycle were evaluated using flow cytometry. An NPC xenograft model in NOD‑SCID mice was used to evaluate the efficacy of the combination therapy of erlotinib with radiation. Erlotinib enhanced the sensitivity of the CNE1 and CNE2 cells to radiation, with sensitization enhancement ratios (SERs) of 1.076 and 1.109, respectively. Erlotinib combined with radiation induced G2/M phase cell cycle arrest in the two cell lines. The mouse tumor model demonstrated a significant reduction in NPC tumor volume in mice treated with erlotinib in combination with radiation when compared with that in mice treated with radiation alone. Erlotinib combined with radiation provoked G2‑M phase cell cycle arrest, thereby enhancing the sensitivity of the NPC cells to radiation.

View Figures

View References

1.	Parkin DM, Whelan SL, Ferlay J, Raymond L and Young J: Cancer Incidence in Five Continents. IARC Scientific Publications. 143:814–815. 1997.
2.	Xiao WW, Huang SM, Han F, et al: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 117:1874–1883. 2011. View Article : Google Scholar
3.	Ng WT, Lee MC, Hung WM, et al: Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 79:420–428. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Song CH, Wu HG, Heo DS, Kim KH, Sung MW and Park CI: Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 118:663–670. 2008. View Article : Google Scholar
5.	Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, et al: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 23:6966–6975. 2005. View Article : Google Scholar
6.	Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 23:6730–6738. 2005. View Article : Google Scholar
7.	Herbst RS and Langer CJ: Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 29(Suppl 4): S27–S36. 2002. View Article : Google Scholar : PubMed/NCBI
8.	Meche A, Cimpean AM and Raica M: Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer. Rom J Morphol Embryol. 50:217–221. 2009.PubMed/NCBI
9.	Hirsch FR, Varella-Garcia M and Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 28(Suppl 1): S32–S37. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Leong JL, Loh KS, Putti TC, Goh BC and Tan LK: Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope. 114:153–157. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Yuan TZ, Li XX, Cao Y, Qian CN, Zeng MS and Guo X: Correlation of epidermal growth factor receptor activation to metastasis-free survival of nasopharyngeal carcinoma patients. Ai Zheng. 27:449–454. 2008.(In Chinese).
12.	Yuan Y, Zhou X, Song J, et al: Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 117:192–200. 2008.PubMed/NCBI
13.	Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:4838–4848. 1997.PubMed/NCBI
14.	Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 291:739–748. 1999.
15.	Ng SS, Tsao MS, Nicklee T and Hedley DW: Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 1:777–783. 2002.PubMed/NCBI
16.	Chinnaiyan P, Huang S, Vallabhaneni G, et al: Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 65:3328–3335. 2005.
17.	Ma BB, Poon TC, To KF, et al: Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck. 25:864–872. 2003. View Article : Google Scholar
18.	Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab induced rash and survival. Lancet Oncol. 11:21–28. 2010.PubMed/NCBI
20.	Nyati MK, Morgan MA, Feng FY and Lawrence TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 6:876–885. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Tortora G, Gelardi T, Ciardiello F and Bianco R: The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int J Biol Markers. 22(Suppl 4): S47–S52. 2007.PubMed/NCBI
22.	Bai XX, Mou XX, Jiang SJ, et al: Effects of Erlotinib on apoptosis in human pulmonary adenocarcinoma. Chinese Journal of Gerontology. 30:1073–1076. 2010.(In Chinese).
23.	Xiong X, Liu H, Fu L, et al: Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. Chemotherapy. 54:463–474. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Huang S, Armstrong EA, Benavente S, Chinnaiyan P and Harari PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64:5355–5362. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Sarkaria JN, Carlson BL, Schroeder MA, et al: Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 12:2264–2271. 2006. View Article : Google Scholar : PubMed/NCBI